Antimicrobial foam dressing substitution

AC-2025-047ClosedFast Track· Wound Care· Owner: Sarah Okafor· Target decision: Dec 16, 2025
View the Aval
overviewevidenceevaluationfinancialimplementationdecisionvalueaudit
Decision record
Outcome
Approved
Decided
Dec 16, 2025
Votes
3 for · 0 against · 0 abstentions
Rationale
Equivalent clinical performance in sample evaluation; 19% category saving. Delegated fast-track authority.
Signatories
Sarah Okafor (Director, Value Analysis); Alan Chen (VP, Supply Chain & Facilities)
View the Aval — the signed decision record and value contract →